---
figid: PMC4100983__cbt-15-826-g4
figlink: /pmc/articles/PMC4100983/figure/F4/
number: ''
caption: Figure 4. Model of BRAFV600E-dependent cell growth and mechanisms of resistance
  to BRAF inhibition and restoring of drug sensitivity through combination therapies.
  BRAF mutation confers constitutive pathway activation (red arrows) independent of
  upstream RTKs (EGFR, IGF-1R)/RAS signaling (left panel), providing an explanation
  to the observed insensitivity to anti-EGFR antibody treatment (panitumumab, cetuximab)
  in BRAF mutant CRC. Such a process is blunted by BRAFV600E (BRAFmut) inhibitors
  (blue symbols and drugs) (right panel). Additional mechanisms of EGFR primary or
  secondary resistance described in lung, head-neck cancer and CRC (i.e., EGFR mutation;
  oncogenic shift or activation of a bypass pathway such as KRAS, BRAF, PIK3CA, secondary
  EGFR mutation or a parallel/alternative pathway [PTEN, IGF1] is also indicated).
  Right panel also illustrates how bypass and resistance to BRAF-inhibitors may occur
  through the rescue of the BRAFV600E-mediated attenuation of ERK negative feedback
  induced by BRAF inhibitors and subsequent reactivation of ligand-dependent signaling
  from EGFR or IGF-1R or via wild type RAS/RAF or PIK3CA/AKT or PIK3CA or EGFR or
  MEK1 or further BRAF gain-of-function mutations (PIK3CAmut or asterisks) in several
  tumor types. Drugs under development in preclinical models or clinical trials to
  overcome BRAF inhibitor resistance are labeled in blue. References are quoted in
  the text.
pmcid: PMC4100983
papertitle: Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated
  metastatic colorectal cancer.
reftext: Carlo Capalbo, et al. Cancer Biol Ther. 2014 Jul 1;15(7):826-831.
pmc_ranked_result_index: '14229'
pathway_score: 0.9484794
filename: cbt-15-826-g4.jpg
figtitle: Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated
  metastatic colorectal cancer
year: '2014'
organisms: Homo sapiens
ndex: 1a34ea5f-dedf-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4100983__cbt-15-826-g4.html
  '@type': Dataset
  description: Figure 4. Model of BRAFV600E-dependent cell growth and mechanisms of
    resistance to BRAF inhibition and restoring of drug sensitivity through combination
    therapies. BRAF mutation confers constitutive pathway activation (red arrows)
    independent of upstream RTKs (EGFR, IGF-1R)/RAS signaling (left panel), providing
    an explanation to the observed insensitivity to anti-EGFR antibody treatment (panitumumab,
    cetuximab) in BRAF mutant CRC. Such a process is blunted by BRAFV600E (BRAFmut)
    inhibitors (blue symbols and drugs) (right panel). Additional mechanisms of EGFR
    primary or secondary resistance described in lung, head-neck cancer and CRC (i.e.,
    EGFR mutation; oncogenic shift or activation of a bypass pathway such as KRAS,
    BRAF, PIK3CA, secondary EGFR mutation or a parallel/alternative pathway [PTEN,
    IGF1] is also indicated). Right panel also illustrates how bypass and resistance
    to BRAF-inhibitors may occur through the rescue of the BRAFV600E-mediated attenuation
    of ERK negative feedback induced by BRAF inhibitors and subsequent reactivation
    of ligand-dependent signaling from EGFR or IGF-1R or via wild type RAS/RAF or
    PIK3CA/AKT or PIK3CA or EGFR or MEK1 or further BRAF gain-of-function mutations
    (PIK3CAmut or asterisks) in several tumor types. Drugs under development in preclinical
    models or clinical trials to overcome BRAF inhibitor resistance are labeled in
    blue. References are quoted in the text.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGF1R
  - MAP2K1
  - PIK3CA
  - PIK3R6
  - PIK3CB
  - MTOR
  - MAPK3
  - EGFR
  - NRAS
  - HRAS
  - PIK3R3
  - PIK3R4
  - MAP2K2
  - KRAS
  - RAF1
  - MAPK1
  - BRAF
  - PIK3CD
  - ARAF
  - PIK3R5
  - PIK3CG
  - Perifosine
  - Selumetinib
  - Dacomitinib
  - BEZ235
  - BMS754807A
  - Trametinib
  - Dabrafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: IGF-1R+
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: -ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: -ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
chemicals:
- word: Perifosine
  source: MESH
  identifier: C105905
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Dacomitinib
  source: MESH
  identifier: C525726
- word: BEZ235
  source: MESH
  identifier: C531198
- word: BMS754807A
  source: MESH
  identifier: C545990
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
